A combined diphtheria, tetanus, five-component acellular pertussis, poliovirus andHaemophilus influenzaetype b vaccine

1 December 2005

journal article
research article
Published by Taylor & Francis in Expert Review of Vaccines

Vol. 4 (6) , 793-805
https://doi.org/10.1586/14760584.4.6.793

Abstract

Ideally, combination vaccines should not only be safe and effective, but also integrate smoothly into the vaccination schedule and provide advantages over the use of separately administered vaccines. Pentaceltrade mark (Sanofi Pasteur Ltd., Toronto, Canada), a combination vaccine first licensed in Canada and subsequently in other countries, is immunogenic against diphtheria, tetanus, pertussis, polio and Haemophilus influenzae type b when administered at 2, 4, 6 and 15-18 months of age. In published studies, the safety, immunogenicity and effectiveness of this combination vaccine were comparable with those of separately administered vaccines, with the advantage of a simplified dosing schedule.

Keywords

This publication has 23 references indexed in Scilit:

Invasive Haemophilus influenzae type b infections in vaccinated and unvaccinated children in Canada, 2001-2003
CMAJ : Canadian Medical Association Journal, 2005
The Changing Age and Seasonal Profile of Pertussis in Canada
The Journal of Infectious Diseases, 2002
Development, Acceptance, and Use of Immunologic Correlates of Protection in Monitoring the Effectiveness of Combination Vaccines
Clinical Infectious Diseases, 2001
Haemophilus influenzae Type b Vaccine: Reconstitution of Lyophilised PRP-T Vaccine with a Pertussis-containing Paediatric Combination Vaccine, or a Change in the Primary Series Immunisation Schedule, May Modify the Serum Anti-PRP Antibody Responses
Current Medical Research and Opinion, 2001
Magnitude of Interference after Diphtheria‐Tetanus Toxoids–Acellular Pertussis/Haemophilus influenzaeType b Capsular Polysaccharide–Tetanus Vaccination Is Related to the Number of Doses Administered
The Journal of Infectious Diseases, 2001
Combination Vaccines
Infectious Disease Clinics of North America, 2001
Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis
The Lancet, 1999
Safety and Immunogenicity of Haemophilus influenzae‐Tetanus Toxoid Conjugate Vaccine Given Separately or in Combination with a Three‐Component Acellular Pertussis Vaccine Combined with Diphtheria and Tetanus Toxoids and Inactivated Poliovirus Vaccine for the First Four Doses
Clinical Infectious Diseases, 1999
Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine
The Lancet, 1997
A Controlled Trial of a Two-Component Acellular, a Five-Component Acellular, and a Whole-Cell Pertussis Vaccine
New England Journal of Medicine, 1996